Objective

2

To observe the efficacy of Yuebi Jia Banxiatang on old patients with community acquired pneumonia （CAP） combined with syndrome of phlegm heat damming lung， and observe effect on inflammatory markers and prognosis.

Method

2

A total of 120 patients with CAP were randomly divided into control group （60 cases） and observation group （60 cases） by random number table. In control group， 55 patients finished the therapy （3 patients fell off or were lost to follow-up， 2 were eliminated）， 55 patients in observation group completed the therapy （5 patients fell off or were lost to follow-up）. Both groups' patients got anti-infection and other comprehensive therapies. Patients in control group got Feilike mixture， 20 mL/time， 3 times/day. Patients in observation group obtained Yuebi Jia Banxiatang， 1 dose/day. The course of treatment for the two groups continued for 10 days. Antipyretic time and antipyretic rate at the 5

th

day after treatment， relief time of cough， expectoration and lung rale were recorded. And clinical pulmonary infection score （CPSI）， time （CPSI

<

6） and time to stop antibiotics were recorded. Before and after treatment， syndrome of phlegm heat damming lung was scored， and failure of initial treatment was also recorded. Levels of procalcitonin （PCT）， red blood cell volume distribution wid （RDW），

D

-dimer （

D

-D） and synpeptin， high sensitivity C-reactive protein （hs-CRP）， tumor necrosis factor-

α

（TNF-

α

）， interleukin （IL-1

β

） and IL-6 were measured. Recurrence rate of chest radiograph was recorded， and safety was evaluated.

Result

2

Relief time of antipyretic， cough， expectoration and lung rale in observation group were less than those in control group （

P

<

0.01）. Antipyretic rate at the 5

th

day after treatment， antibiotic discontinuation rate， recurrence rate of chest radiograph were 85.45% （47/55）， 94.55% （52/55） and 90.91% （50/55）， which were higher than 65.45% （36/55）， 81.82% （45/55） and 74.55% （45/55） in control group. And initial treatment failure rate was 5.54% （3/55）， which was lower than 20.00% （11/55） in control group （

P

<

0.05）. Scores of CPSI and syndrome of phlegm heat damming lung were less than those in control group （

P

<

0.01）. And levels of PCT， RDW，

D

-D， peptide， hs-CRP， TNF-

α

， IL-1

β

and IL-6 were all below the level in control group （

P

<

0.01）. Total effective rate of traditional Chinese medicine （TCM） syndrome was 96.36% （53/55）， which was higher than 83.64% （46/55） in control group （

χ

2

=4.949，

P

<

0.05）. And there was no adverse reactions relating to traditional Chinese medicine.

Conclusion

2

In addition to anti-infection and other comprehensive therapies， Yuebi Jia Banxiatang can control the clinical symptoms， reduce the degree of pulmonary infection and disease， control the inflammatory reaction， shorten the course of disease and improve the prognosis， with a significant effect and safety in clinical use.